Skip to main content
. 2022 Nov 23;12:1043177. doi: 10.3389/fonc.2022.1043177

Figure 7.

Figure 7

ZNF24 promotes the growth of KRAS mutant lung adenocarcinoma grafts via SLC7A5. (A) Transplanted tumor model in nude mice by subcutaneous injection of tumor cells. (B) In vivo imaging of mice showed that the tumor growth rate was significantly delayed after knockdown of ZNF24, and the inhibition of ZNF24 could be partially reversed after recovery of SLC7A5. (C–E) Measurement of the primary tumor volume and weight. ZNF24 promoted tumor growth through SLC7A5. (F), HE staining showed focal necrosis of cells in shZNF24 group but massive necrosis of cells in NC and shZNF24+OE-SLC7A5 groups. Immunohistochemical staining showed that the SLC7A5 was expressed in membrane (green arrow) and nucleus (red arrow) of tumor, and the expression was significantly less in shZNF24 group than in NC and shZNF24+OE-SLC7A5 groups. There were less Ki-67 positive tumor cells in shZNF24 group than in NC and shZNF24+OE-SLC7A5 groups. NC, negative control; OE, overexpression. Data are shown as means ± SD. P values were calculated with two-tailed paired Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.